Insys Therapeutics (NASDAQ:INSY) Stock Rating Reaffirmed by Oppenheimer

Insys Therapeutics (NASDAQ:INSY)‘s stock had its “hold” rating reissued by stock analysts at Oppenheimer in a report released on Sunday, March 11th.

Several other research firms have also recently weighed in on INSY. Zacks Investment Research cut Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd. Cann reissued an “average” rating on shares of Insys Therapeutics in a research report on Friday, March 2nd. ValuEngine raised Insys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, Piper Jaffray cut Insys Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday, March 9th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Insys Therapeutics has a consensus rating of “Hold” and an average target price of $9.38.

Insys Therapeutics stock traded down $0.30 during trading on Friday, hitting $6.26. 400,785 shares of the company were exchanged, compared to its average volume of 1,361,826. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.02. The company has a market capitalization of $472.09, a P/E ratio of -12.78 and a beta of 1.13.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.47). Insys Therapeutics had a negative return on equity of 24.02% and a negative net margin of 162.07%. The company had revenue of $31.49 million for the quarter, compared to the consensus estimate of $34.00 million. During the same quarter last year, the company posted $0.03 EPS. The company’s quarterly revenue was down 42.6% compared to the same quarter last year. sell-side analysts anticipate that Insys Therapeutics will post -0.83 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in INSY. Wells Fargo & Company MN raised its stake in shares of Insys Therapeutics by 0.5% during the 2nd quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock valued at $350,000 after purchasing an additional 126 shares during the period. TIAA CREF Investment Management LLC raised its stake in shares of Insys Therapeutics by 3.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 64,048 shares of the specialty pharmaceutical company’s stock valued at $810,000 after purchasing an additional 2,250 shares during the period. Northern Trust Corp raised its stake in shares of Insys Therapeutics by 3.2% during the 2nd quarter. Northern Trust Corp now owns 314,825 shares of the specialty pharmaceutical company’s stock valued at $3,983,000 after purchasing an additional 9,906 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of Insys Therapeutics by 31.1% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,712 shares of the specialty pharmaceutical company’s stock valued at $426,000 after purchasing an additional 8,000 shares during the period. Finally, Voya Investment Management LLC bought a new stake in shares of Insys Therapeutics during the 2nd quarter valued at $149,000. Institutional investors own 24.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insys Therapeutics (NASDAQ:INSY) Stock Rating Reaffirmed by Oppenheimer” was first published by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://baseballnewssource.com/2018/04/05/insys-therapeutics-insy-hold-rating-reaffirmed-at-oppenheimer/2027135.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.